Preliminary clinical study of recombinant human endostatin combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancer and the patients suitable for this therapy
10.3760/cma.j.issn.1674-6554.2014.02.008
- VernacularTitle:内皮抑素联合放疗治疗肺癌脑转移及其获益人群筛选的临床研究
- Author:
Xiaodong JIANG
;
Manhua DING
;
Yun QIAO
;
Yi LIU
;
Liang LIU
;
Peng DAI
;
Daan SONG
- Publication Type:Journal Article
- Keywords:
Recombinant human endostatin;
Radiotherapy;
Vascular endothelial growth factor receptor 2;
Lung cancer;
Brain metastases
- From:
Chinese Journal of Behavioral Medicine and Brain Science
2014;23(2):122-125
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic effects of recombinant human endostatin (RHES) combined with radiotherapy on brain metastases (BM) of non-small cell lung cancer (NSCLC) and the patients suitable for this therapy.Methods Eighty patients with BM of NSCLC were randomly divided into RHES combined with radiotherapy group (combination group) and radiotherapy alone group (each group with 40 patients).The short-term effective rate,overall survival time,cerebral edema index and adverse reactions were observed and the expressions of vascular endothelial growth factor receptor 2 (VEGFR2) protein in primary lesions were detected with immunohistochemical method in all patients.Results Compared with radiotherapy alone group,brain edema was significantly relieved (t=4.9,P=0.000) and there were no marked adverse reactions in combination group.In short-term effective rate,there was no statistical significance in total population (n=80,90％ vs.75％,x2=3.11,P=0.07),but there was statistical significance in the patients with positive VEGFR2 (93％ vs.67.7％,x2=6.31,P=0.012).In overall survival time,there was no statistical significance in total population (n=80,P=0.35,95％ CI:0.25-1.30) or in the patients with positive VEGFR2 (P=0.109,95％ CI:0.40-1.34).Conclusion Compared with radiotherapy alone,RHES combined with radiotherapy can relieve brain edema in the patients with BM of NSCLC and obtain better short-term effective rate in the patients with positive VEGFR2.
